Department of Nutrition, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders.
Chongqing Key Laboratory of Paediatrics, Chongqing Key Laboratory of Child Health and Nutrition.
Asia Pac J Clin Nutr. 2021;30(1):113-121. doi: 10.6133/apjcn.202103_30(1).0014.
This study evaluated the impact of 12 months of ketogenic dietary treatment (KDT) on growth in Chinese infants with refractory epilepsy.
The KDT group included patients who were divided into groups A (age 6-12 months), B (12-24 months) and C (24-36 months). The normal group included infants aged approximately 6-12 months, 12-24 months and 24-36 months who were classified into groups A1, B1 and C1, respectively. Data on height, weight, aspartate transaminase (AST), alanine transaminase (ALT), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), zinc, iron, calcium, magnesium, and haemoglobin (Hb) were extracted from the medical records. Then, we compared the impacts of 12 months of KDT on growth.
Forty-one patients were included in the KDT group, and 90 infants were included in the normal group. The overall prevalence of underweight (WAZ <-2 SD), stunting (HAZ <-2 SD), wasting (BAZ <-2 SD), and overweight/obesity (BAZ ≥2 SD) were relatively lower in the A and B groups. The prevalence of anaemia in group A was significantly higher than that in group A1. No significant differences were observed in the KDT groups with regard to HDL, LDL, AST, ALT, iron, calcium, magnesium, or zinc. A greater than 50% reduction in weekly seizure frequency was evident in 100% of group A, 78.6% of group B and 77.8% of group C.
The results revealed that patients less than 2 years old who received KDT maintained appropriate growth at the 12-month follow-up.
本研究评估了 12 个月生酮饮食治疗（KDT）对中国难治性癫痫婴儿生长的影响。
KDT 组包括分为 A 组（6-12 个月）、B 组（12-24 个月）和 C 组（24-36 个月）的患者。正常组包括年龄分别为 6-12 个月、12-24 个月和 24-36 个月的婴儿，分别归入 A1、B1 和 C1 组。从病历中提取身高、体重、天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TGs）、锌、铁、钙、镁和血红蛋白（Hb）的数据。然后，我们比较了 12 个月 KDT 对生长的影响。
KDT 组纳入 41 例患者，正常组纳入 90 例婴儿。A 组和 B 组整体消瘦（WAZ <-2 SD）、发育迟缓（HAZ <-2 SD）、消瘦（BAZ <-2 SD）和超重/肥胖（BAZ ≥2 SD）的发生率相对较低。A 组贫血发生率明显高于 A1 组。KDT 组 HDL、LDL、AST、ALT、铁、钙、镁或锌无显著差异。A 组、B 组和 C 组各有 100%、78.6%和 77.8%的患者每周癫痫发作频率减少 50%以上。
结果表明，接受 KDT 的 2 岁以下患者在 12 个月随访时生长状况适宜。
